It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Explore the question of which is better for daily expenses: cash back or points. Make informed choices to maximize your rewards potential.
27,346 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As the 2026 market landscape bifurcates, Walmart emerges as a potential hedge, supported by strong Q4 results, expand...
Circle announces a $222 million Arc token presale at a $3 billion FDV, drawing major investors as quarterly revenue g...
QYLD offers a headline 12% yield through its covered-call strategy, yet 10-year total returns lag the Nasdaq-100 and ...
A director at Arteris disclosed disposing over 20,000 shares, split between a gift and an open-market sale. Here’s ho...
Stocks paused after a sharp tech selloff, led by Micron and Intel. Yet one tech name stood out, bucking the trend as ...
When blue-chip allocators signal interest in a landmark IPO, it reshapes how individual investors view the stock. Thi...
NVIDIA is expanding beyond chips into cloud AI infrastructure. This move signals a broader AI ecosystem pivot that co...
Tensions in the Persian Gulf surged after Bahrain said 41 people were detained in a crackdown tied to Iran’s Revoluti...
As Congress debates a sweeping housing bill, lenders and manufacturers warn about misaligned incentives. This opinion...
Two new AI music models from ElevenLabs and Stability AI promise bigger creative horizons, with open weights and long...
Tech leaders are shifting in 2026, prompting a clash between QQQ and VGT for access to Big Tech. This report breaks d...